Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.

The oncologist·2026
Same author

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2025
Same author

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.

The Lancet. Oncology·2025
Same author

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.

Cell reports. Medicine·2025
Same author

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

The Lancet. Oncology·2025

Related Experiment Video

Updated: Apr 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

PD-L1 inhibition with MPDL3280A for solid tumors.

Edward Cha1, Jeffrey Wallin2, Marcin Kowanetz2

  • 1Product Development Oncology, Genentech, Inc, South San Francisco, CA.

Seminars in Oncology
|May 13, 2015
PubMed
Summary

Cancer immunotherapy using anti-PD-L1 antibodies like MPDL3280A shows promise. This approach is most effective in patients whose immune systems are suppressed by PD-L1 and can be reinvigorated by the antibody treatment.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Cancer immunotherapy is a growing field aiming to boost anti-tumor immune responses.
  • Monoclonal antibodies targeting the PD-L1/PD-1 pathway offer a promising therapeutic strategy with good tolerability across various cancers.

Purpose of the Study:

  • To review the safety, clinical activity, and biomarker data of the anti-PD-L1 antibody MPDL3280A.
  • To evaluate MPDL3280A in a phase Ia multicenter trial.

Main Methods:

  • A phase Ia multicenter, dose-escalation and -expansion trial was conducted.
  • Safety, clinical activity, and biomarker data were collected and analyzed.

Main Results:

  • MPDL3280A demonstrated a safety profile suitable for clinical use.
  • Clinical activity was observed, particularly in patients with specific biomarker profiles.
  • Data suggest effectiveness in patients with PD-L1-suppressed immunity that is restored by treatment.

Conclusions:

  • MPDL3280A is a well-tolerated anti-PD-L1 antibody with demonstrated clinical activity.
  • The antibody shows particular efficacy in patients with pre-existing PD-L1-mediated immune suppression.